The webinar “Novel Agents in Multiple Myeloma: Exploring Drug Resistance and New Opportunities” organized by Cancer Drug Resistance and chaired by Dr. Giovanni Martinelli and Dr. Claudio Cerchione from the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl-IRCCS, Italy was held successfully on October 13, 2022.

Six Guest Speakers delivered their speeches and shared their researches and insights on different topics of multiple myeloma in the webinar.

Speaker 1:

Dr. Fabio Malavasi, Department of Medical Sciences, University of Torino, Torino, Italy.
Topic: Anti-CD38 antibody therapy: basic science and combined immunotherapy strategies

Speaker 2:

Dr. Carolina Terragna, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
Topic: Molecular biology in myeloma

Speaker 3:

Dr. Claudio Cerchione, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl-IRCCS, Meldola, Italy.
Topic: How I manage multiple myeloma - state of the art

Speaker 4:

Dr. Alessandro Gozzetti, Hematology, University of Siena, Policlinico Le Scotte, Siena, Italy.
Topic: Daratumumab treatment for multiple myeloma patients in >VGPR but MRD positive by NGF after 1st line therapy

Speaker 5:

Dr. Giovanni Martinelli, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl-IRCCS, Meldola, Italy.
Topic: Importance of network in multiple myeloma: where are we going?

Speaker 6:

Dr. Daniela de Totero, Molecular Pathology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Topic: The HGF/c-MET axis as a potential target to overcome survival signals and improve therapeutic efficacy in multiple myeloma

Cancer Drug Resistance appreciates the Chairs Dr. Giovanni Martinelli and Dr. Claudio Cerchione and all Guest Speakers again for the substantial effort to make this webinar a great success.

For more details of the webinar, please visit: https://cdrjournal.com/journal/webinar.